Year: 2024
Type: article
Study design: Case Report
Abstract: COVID-19 vaccines are globally administered and generally safe.However, rare cutaneous adverse effects have been reported.We report a 37-year-old woman who developed new-onset guttate psoriasis five days after receiving the Pfizer/BioNTech COVID-19 vaccine.Initial treatment with cyclosporine and topical calcipotriol/betamethasone showed limited efficacy necessitating a switch to methotrexate and NBUVB which resulted in improvement over 3 months.New-onset psoriasis following COVID-19 vaccination is primarily managed with topical treatments, with guttate psoriasis showing a better prognosis compared to other subtypes.This case underscores the need for individualized treatment approaches and highlights the importance of recognizing vaccine-associated psoriasis.
Source: Daehan geonseon hakoeji (Online)
Institution: Hallym University Sacred Heart Hospital
Language: English
Subfield: Dermatology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W4405877757